Association Between CHEK2*1100delC and Breast Cancer: A Systematic Review and Meta-Analysis
The association between the checkpoint kinase 2*1100delC (CHEK2*1100delC) and breast cancer has been extensively explored.
In light of the recent publication of studies on these specific findings, particularly regarding male patients with breast cancer, we performed an updated meta-analysis to investigate a more reliable estimate.
This meta-analysis included 26 published studies selected in a search of electronic databases up to January 2018, including 118,735 breast cancer cases and 195,807 controls. Odds ratios (ORs) with 95% confidence intervals (CIs) were used to assess the association between 1100delC and breast cancer.
Meta-analysis results suggested that 1100delC contributed to an increased breast cancer risk in overall populations (OR 2.89; 95% CI 2.63–3.16). Subgroup analysis found ORs of 3.13 (95% CI 1.94–5.07) for male breast cancer, 2.88 (95% CI 2.63–3.16) for female breast cancer, 2.87 (95% CI 1.85–4.47) for early-onset breast cancer, 2.92 (95% CI 2.65–3.22) for invasive breast cancer, and 3.21 (95% CI 2.41–4.29) for familial breast cancer. The sensitivity analysis suggested that results of this meta-analysis were generally robust.
CHEK2*1100delC is associated with an increased risk of both female and male breast cancer.
Compliance with Ethical Standards
No sources of funding were used to conduct this study or prepare this manuscript.
Conflict of Interest
ML, YZ, CS, FKR, MM, TS, YS have no conflicts of interest.
This article does not contain any studies with human participants or animals performed by any of the authors.
- 15.Moher D, Liberati A, Tetzlaff J, Altman DG. PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann Intern Med. 2009;151(264–9):W64.Google Scholar
- 16.Wells GA, Shea B, O’Connell D, et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality if nonrandomized studies in meta-analyses. Ottawa Hospital Research Institute. 2009. http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp. Accessed 5 February 2018.
- 17.Sharp, S. 1998. sbe23: Meta-analysis regression. Stata Technical Bulletin 42: 16-22. Reprinted in Stata Technical Bulletin Reprints, vol. 7, pp. 148-155. College Station, TX: Stata Press.Google Scholar
- 19.Higgins JP, Thompson SG, Deeks JJ, Altman DG. Cochrane handbook for systematic reviews of interventions version 5.1.0. The Cochrane Collaboration 2011.Google Scholar
- 51.The CHEK2 Breast Cancer Case-Control Consortium. CHEK2*1100delC and susceptibility to breast cancer: a collaborative analysis involving 10,860 breast cancer cases and 9065 controls from 10 studies. Am J Hum Genet. 2004;74(6):1175–82. https://doi.org/10.1086/421251.CrossRefPubMedCentralGoogle Scholar
- 53.Adank MA, Verhoef S, Oldenburg RA, Schmidt MK, Hooning MJ, Martens JW, et al. Excess breast cancer risk in first degree relatives of CHEK2 *1100delC positive familial breast cancer cases. Eur J Cancer (Oxford, England: 1990). 2013;49(8):1993–9. https://doi.org/10.1016/j.ejca.2013.01.009.CrossRefGoogle Scholar
- 60.Song CG, Hu Z, Yuan WT, et al. CHEK2 c. 1100delC may not contribute to genetic background of hereditary breast cancer from Shanghai of China. Chin. J Med Genet. 2006;23:443–5.Google Scholar